Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
about
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitorsFibrinogen concentrate in bleeding patientsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitorsRecombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitorsShould prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patientsHaemophilia B: Christmas disease.Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization.Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.Haemophilia A: meeting the needs of individual patients.Proteomics: applications in transfusion medicine.Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasmaRecommendations for the transfusion of plasma and platelets.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia AImmune tolerance induction for patients with severe hemophilia A: a critical literature review.Operative management and outcomes in children with congenital bleeding disorders: a retrospective review at a single haemophilia treatment centre.Tertiary prophylaxis in adults: is there a rationale?Haemophilia B: current pharmacotherapy and future directions.Current management of hemophilia B: recommendations, complications and emerging issues.Recombinant proteins in therapeutics: haemophilia treatment as an example.Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.Recommendations for the use of antithrombin concentrates and prothrombin complex concentratesHaemophilia part 1: an introduction.An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors.Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Efficient factor VIII affinity purification using a small synthetic ligand.In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency.Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application.Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.Haemophilia
P2860
Q24187069-9091E9A1-0BE0-4978-8748-89C3A7F7579DQ24200171-E0CC0520-01DB-425B-9E57-8F327F604227Q24236388-12DAE887-D21F-41C1-BA21-66F45A3C0BA2Q24247217-7B1159A7-98E8-4DEF-9FB5-8F38DF961552Q31129968-CDD532AC-A649-4A0E-AE75-31D3EE1AA729Q33959616-72781ACC-5EF6-4C56-898A-3BDA8EBE7101Q36221979-E50415D9-F03E-400B-B8E4-1E234F254A85Q36366931-E86BF768-4183-4DC6-A71B-74C37BA94467Q36533439-BEFF05FC-B617-4AD8-A01A-0B84B17BE4F6Q36536149-BDAFCE4D-A319-41A2-A9DE-4BB4017FBCFBQ36969491-F07A3E0E-1ED3-4F43-A47F-AE7FB2BC01BDQ37008132-32E18147-B3DC-4CC3-AB5A-4A152F544AACQ37062388-7B7040F2-896E-4C18-95EB-2F097B67D61FQ37062415-E4297745-A246-4B62-9302-330D9EFB9C5EQ37209117-715B2643-EA54-47AB-A13C-84631355D06AQ37303186-E058F062-D5F5-42FD-B450-5CFDDA77E82CQ37912059-3A03F4B6-CA4F-482E-8AA1-0CF2F0981473Q37942603-65AC5F30-1695-437B-954F-C3CF33BECDC3Q38013763-C13AE069-7B9D-4A66-81EA-E1B14620BF5CQ38040458-89307591-213A-4B45-9490-D04FC38AF717Q38238972-CB8444EA-86E0-45BB-9533-0AD5136AE1FAQ38444981-F22DB5ED-7769-4280-B116-0B46F5D108D7Q38743779-1E500E96-DE48-4985-8E37-B0F59091358CQ39648285-A83CC49C-6A67-4137-8DA8-F619B602934FQ42096335-83EAE6EA-257B-4308-B393-9AF936C3B4C6Q45213003-6D40C53D-D491-4D1A-82DB-072107CFA9BBQ45855778-A4FA20D2-1690-42DA-80A5-AF21EA130F4CQ45863628-A72A5E30-FF90-46B1-BF0D-FCEEC346EC1AQ45863828-97672C96-7147-4D98-A0C0-21E411017E86Q45868033-0F9B20B5-6022-45DE-B4CA-533427EE4193Q45868043-1A1ED3DF-C48F-4610-8254-034A01B0B40EQ45874455-7A21FF81-224B-4DA8-BE0E-2DB1EA2A070EQ45880602-0DD8EE7B-4CA0-4A4A-BBBE-132A00A9FA6AQ48543476-E3DC13B4-C204-42FB-98DE-191E23DC387AQ50959861-47D620BD-EA83-4772-8CCA-0D805F5C4A55Q53240284-5144C3A1-1122-402E-ACE3-40BAD0094126Q58736865-C6D0956F-0499-4FCB-A16C-B0CAB7660C82
P2860
Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Guidelines on the selection an ...... hereditary bleeding disorders.
@en
Guidelines on the selection an ...... hereditary bleeding disorders.
@nl
type
label
Guidelines on the selection an ...... hereditary bleeding disorders.
@en
Guidelines on the selection an ...... hereditary bleeding disorders.
@nl
prefLabel
Guidelines on the selection an ...... hereditary bleeding disorders.
@en
Guidelines on the selection an ...... hereditary bleeding disorders.
@nl
P2860
P1433
P1476
Guidelines on the selection an ...... hereditary bleeding disorders.
@en
P2093
United Kingdom Haemophelia Centre Doctors' Organisation
P2860
P356
10.1046/J.1365-2516.2003.00711.X
P577
2003-01-01T00:00:00Z